Header Logo

Connection

Robin Jones to Receptor, ErbB-2

This is a "connection" page, showing publications Robin Jones has written about Receptor, ErbB-2.
Connection Strength

0.385
  1. Nuclear NF-?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol. 2011 Feb; 64(2):130-5.
    View in: PubMed
    Score: 0.088
  2. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1197-213.
    View in: PubMed
    Score: 0.086
  3. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(2):315-23.
    View in: PubMed
    Score: 0.078
  4. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007 Dec; 106(2):181-9.
    View in: PubMed
    Score: 0.067
  5. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006 Oct; 7(10):869-74.
    View in: PubMed
    Score: 0.066
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.